PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2015

Oct 26, 2015

Rule 3.19A.2

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Antisense Therapeutics Limited (ASX:ANP)
ABN:	41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Robert W Moses
Date of Last Notice:	20th July 2015

Part 1 – Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct
Nature of indirect interest	N/A
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.Date of change
	21st & 22nd October 2015
No. of securities held prior to change
		Shares	Options
	Direct	3,254,434	708,001
	Indirect	-
	Total	3,254,434	708,001
Class	Ordinary Shares
Number acquired		Shares	Options
	Direct	100,000	-
	Indirect	-	-
	Total	100,000	-
Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-

+ See chapter 19 for defined terms.

Appendix 3Y

Value/ConsiderationNote: If consideration is non-cash, provide details andestimated valuation	$0.086 cents per share
No. of securities held after change		Shares	Options
	Direct	3,354,434	708,001
	Indirect	-
	Total	3,354,434	708,001
Nature of changeExample: on-market trade, off-market trade, exercise ofoptions, issue of securities under dividend reinvestment plan,participation in buy-back	On-Market Acquisition

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest relatedprior to changeNote: Details are only required for a contract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contractsdetailed above traded during a +closed period whereprior written clearance was required?	No
If so, was prior written clearance provided to allow
the trade to proceed during this period?	N/A
If prior written clearance was provided, on what
date was this provided?	N/A

The CFO Solution

27/10/2015

+ See chapter 19 for defined terms.